世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000031298

アルツハイマー病治療薬の世界市場:薬剤クラス別・流通チャネル別・地域別・国別の分析(2022年版)- COVID-19の影響による市場の洞察、パイプライン、および予測(2022年〜2027年)

Azoth Analytics

Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)

発刊日 2022/01/31

言語英語

体裁PDF/220ページ

ライセンス/価格220ページ

0000031298

Single
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

2021年の世界のアルツハイマー病治療薬市場は65億3,700万米ドルと評価されています。

糖尿病、肥満、心臓病、高血圧に加え、座りがちな生活、不健康な食事パターン、喫煙は、アルツハイマー病の発症の可能性を高める要因として知られています。高齢者人口の増加と相まって、これらの疾患の有病率やライフスタイルの選択肢が増えたことが、市場成長の主な要因の一つとなっています。さらに、大手製薬会社は、病気を予防し、認知機能を長期的に改善する医薬品の開発に注力しています。

また、遠隔医療サービスの拡大やオンライン薬局の普及が、市場の成長をさらに後押ししています。遠隔医療は、遠隔通信技術やデジタル通信技術を通じて、臨床および非臨床サービスを遠隔で提供することと定義されます。これらのプラットフォームは、遠隔地での病気の診断とドラッグデリバリーを可能にしました。 これとは別に、アデュカヌマブ(Aducanumab)やソラネズマブ(Solanezumab)など、さまざまなアルツハイマー病の薬が現在、後期臨床試験中です。 これらの薬の開発は、今後数年間で市場の成長を推進すると予想されます。

さらに、アルツハイマー病の有病率の増加がアルツハイマー病治療薬の需要を喚起し、それが世界のアルツハイマー病治療薬市場を牽引しています。また、製薬会社や研究機関によるアルツハイマー病の効果的な治療法の研究開発活動が活発化していることも、世界のアルツハイマー病治療薬市場を押し上げると予想されます。

調査範囲

  • 本レポートは、アルツハイマー病治療薬市場の過去期間(2017年〜2021年)と予測期間(2022年〜2027年)の分析結果を提供します。
  • 本レポートは、アルツハイマー病治療薬市場を価値(百万米ドル)別に分析しています。
  • 本レポートは、アルツハイマー病治療薬市場を薬剤クラス別(コリン作動性、メマンチン、併用薬、その他)に分析します。
  • 本レポートは、アルツハイマー病治療薬市場を流通チャネル別(病院薬局、小売薬局、オンライン薬局)に分析します。
  • 本レポートは、アルツハイマー病治療薬市場を地域別(北アメリカ、ヨーロッパ、アジア太平洋、LAMEA)に分析します。
  • 本レポートは、アルツハイマー病治療薬市場を国別(アメリカ、カナダ、ドイツ、イギリス、フランス、イタリア、中国、日本、インド、オーストラリア)に分析します。
  • また、市場の魅力は、地域、薬剤クラス、および流通チャネルによって提示されています。
  • また、業界の主要な機会、動向、推進要因、課題が本レポートで分析されています。
  • 本レポートは、競合他社の開発状況、戦略、合併と買収、新製品開発などを追跡しています。

主要企業

  • AbbVie Inc.
  • F. Hoffman-La Roche, Ltd.
  • Novartis AG
  • Biogen
  • Pfizer Inc.
  • Eli Lilli and Company
  • 武田製薬工業(Takeda Pharmaceutical Company Limited)
  • Novo Nordisk
  • 第一三共(Daiichi Sankyo Company Ltd.)
  • エーザイ(Eisai Co. Ltd)
  • NervGen Pharma

レポート詳細

目次

Table of Contents

1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary

2. Strategic Recommendations
3. Alzheimer Drugs Market: Product Outlook

4. Global Alzheimer Drugs Market: Sizing and Forecast
4.1 Global Alzheimer Drugs Market Size, By Value, Year 2017-2027
4.2 Impact of COVID-19 on Global Alzheimer Drugs Market

5. Global Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel
5.1 Competitive Scenario of Global Alzheimer Drugs Market: By Drug Class
5.1.1 Cholinergic - Market Size and Forecast (2017-2027)
5.1.2 Memantine - Market Size and Forecast (2017-2027)
5.1.3 Combined drug - Market Size and Forecast (2017-2027)
5.1.4 Others - Market Size and Forecast (2017-2027)
5.3 Competitive Scenario of Global Alzheimer Drugs Market: By Distribution Channel
5.3.1 Hospitals Pharmacy- Market Size and Forecast (2017-2027)
5.3.2 Retail Pharmacy - Market Size and Forecast (2017-2027)
5.3.3 Online Pharmacy - Market Size and Forecast (2017-2027)

6. Global Alzheimer Drugs Market: Regional Analysis
6.1 Competitive Scenario of Global Alzheimer Drugs Market : By Region

7. North America Alzheimer Drugs Market: An Analysis (2017-2027)
7.1 North America Alzheimer Drugs Market : Size and Forecast (2017-2027), By Value
7.2 North America Alzheimer Drugs Market - Prominent Companies
7.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
7.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
7.5 North America Alzheimer Drugs Market: Country Analysis
7.6 Market Opportunity Chart of North America Alzheimer Drugs Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Alzheimer Drugs Market: By Country
7.8 United States Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
7.9 United States Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
7.10 Canada Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
7.11 Canada Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)

8. Europe Alzheimer Drugs Market: An Analysis (2017-2027)
8.1 Europe Alzheimer Drugs Market : Size and Forecast (2017-2027), By Value
8.2 Europe Alzheimer Drugs Market - Prominent Companies
8.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
8.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
8.5 Europe Alzheimer Drugs Market: Country Analysis
8.6 Market Opportunity Chart of Europe Alzheimer Drugs Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Alzheimer Drugs Market: By Country
8.8 Germany Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.9 Germany Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8.10 United Kingdom Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.11 United Kingdom Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8.12 France Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.13 France Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8.14 Italy Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.15 Italy Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)

9. Asia Pacific Alzheimer Drugs Market: An Analysis (2017-2027)
9.1 Asia Pacific Alzheimer Drugs Market : Size and Forecast (2017-2027), By Value
9.2 Asia Pacific Alzheimer Drugs Market - Prominent Companies
9.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
9.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
9.5 Asia Pacific Alzheimer Drugs Market: Country Analysis
9.6 Market Opportunity Chart Asia Pacific Alzheimer Drugs Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Alzheimer Drugs Market: By Country
9.8 China Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.9 China Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.10 Japan Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.11 Japan Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.12 India Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.13 India Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.14 Australia Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.15 Australia Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)

10. Global Alzheimer Drugs Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends

11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Alzheimer Drugs Market - By Drug Class, 2026
11.2 Market Attractiveness Chart of Global Alzheimer Drugs Market - By Distribution Channel, 2026
11.3 Market Attractiveness Chart of Global Alzheimer Drugs Market - By Region, 2026

12. Competitive Landscape
12.1 Product Pipeline of Leading Alzheimer Drugs Companies
12.2 Market Share Analysis

13. Company Analysis
13.1 AbbVie Inc.,
13.2 F. Hoffman-La Roche, Ltd.
13.3 Novartis AG
13.4 Biogen
13.5 Pfizer Inc.,
13.6 Eli Lilli and Company
13.7 Takeda Pharmaceutical Company Limited
13.8 Novo Nordisk
13.9 Daiichi Sankyo Company Ltd.
13.10 Eisai Co. Ltd
13.11 NervGen Pharma

14. About Us

List of Figures
Global Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Global Number of People With Dementia, in Million, in Low, Middle and High In come Countries, 2015-2020
World’s leading causes of death (in millions), 2019
World Population 65 Years & Above (% of Total), 2015-2019
Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Global Alzheimer - Number of Drugs by Phase, In Percentage, 2020
Global Alzheimer Drugs Market- By Drug Class Market Share, 2021 & 2027
Global Alzheimer Drugs Market- By Cholinergic, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Memantine, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Combined drug, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Others, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Distribution Channel Market Share, 2021 & 2027
Global Alzheimer Drugs Market- By Hospital Pharmacy, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Retail Pharmacy, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Online Pharmacy, By Value (USD Million), 2017-2027
Global Alzheimer Drugs Market- By Region Market Share, 2021 & 2027
North America Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
North America Population ages 65 and above (% of total Population), 2016-2020
United States lifetime risk for Alzheimer's dementia at age 45 and 65 for both Men and Women, 2020 (In %age)
North America Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
North America Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Market Opportunity Chart of North America Alzheimer Drugs Market- By Country, By Value (Year 2017-2027)
North America Alzheimer Drugs Market- By Country Market Share, 2021 & 2027
United States Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
United State Number of People Living with Alzheimer’s Disease, By Age (In Millions), 2020
Alzheimer's disease mortality rate in the United States from 2015 to 2019, (per 100,000 population)
United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
United States Percentage Changes in Selected Causes of Death (All Ages) Between 2000 and 2019, (In %age)
United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
United States Population aged 65 and above (% of total Population), 2016-2020
United State Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
United State Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Canada Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Canada Death Rate for Alzheimer Disease (Per 100,000 Population), 2015-2019
Canada Population aged 65 and above (% of total Population), 2016-2020
Canada Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Canada Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Europe Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
European Countries Population ages 65 and above (% of total Population), 2020
Europe Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Europe Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Figure 48: Market Opportunity Chart of Europe Alzheimer Drugs Market- By Country, By Value (Year 2017-2027)
Europe Alzheimer Drugs Market- By Country Market Share, 2020 & 2026
Germany Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Germany Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Germany Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
United Kingdom Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
United Kingdom Population ages 65 and above (% of total Population), 2016-20
United Kingdom Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
United Kingdom Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
France Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
France Population ages 65 and above (% of total Population), 2016-20
France Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
France Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Italy Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Italy Population ages 65 and above (% of total Population), 2016-20
Italy Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Italy Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Asia Pacific Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Asia Pacific Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Asia Pacific Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Market Opportunity Chart of APAC Alzheimer Drugs Market- By Country, By Value (Year-2026)
APAC Alzheimer Drugs Market- By Country Market Share, 2021 & 2027
China Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
China Population ages 65 and above (% of total Population), 2016-20
China Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
China Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Japan Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Japan Alzheimer’s Drugs company market share (%), 2020
Japan Alzheimer’s Drugs company market share (%), 2020
Japan Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Japan Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
India Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
e-pharmacy market in India (USD million)
India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
India Population ages 65 and above (% of total Population), 2016-20
India Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
India Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Australia Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
Australia current health expenditure (% of GDP), (2014-2018)
Australia population aged 65 and above (% of total population), 2017-2021
Australia urban population (% of total population), 2017-2021
Australia Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Australia Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
Market Attractiveness Chart of Global Alzheimer Drugs Market- By Drug Class (Year-2017-2027)
Market Attractiveness Chart of Global Alzheimer Drugs Market- By Distribution Channel (Year 2017-2027)
Market Attractiveness Chart of Global Alzheimer Drugs Market- By Region (Year 2017-2027)
Global Alzheimer’s Drugs company market share (%), 2020
AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
AbbVie Inc. Net Income (USD Million), 2016-2020
AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Novartis Annual Sales Revenue (USD Million), 2016-2020
Novartis Annual Net Income/Loss (USD Million), 2016-2020
Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Biogen Sales Revenues, 2016-2020 (USD Million)
Biogen Net Profit, 2016-2020 (USD Million)
Biogen, By Business Segment (%), FY2020
Biogen, By Geographical Segment (%), FY2020
Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
Novo Nordisk Sales Revenues, 2016-2020 (USD Million)
Novo Nordisk Net Profit, 2016-2020 (USD Million)
Novo Nordisk Sales Revenue Split, By Business Segment (%), FY2020
Novo Nordisk Sales Revenue Split, By Geography Segment (%), FY2020
Daiichi Sankyo Company Ltd. Revenue, 2020-2021 (In USD Million)
Daiichi Sankyo Company Ltd. Sales Revenue Split, By Business Segment (%), FY2020
Daiichi Sankyo Company Ltd. Sales Revenue Split, By Geography Segment (%), FY2020
Eisai Co. Ltd. Revenue, 2019-2020 (In USD Billion)
Eisai Co. Ltd. Revenue by Reporting Segment, FY2020

List of Tables
Product Pipeline of Leading Alzheimer’s Drugs Companies
Product Pipeline of Leading Alzheimer’s Drugs Companies
Product Pipeline of Leading Alzheimer’s Drugs Companies
Product Pipeline of Leading Alzheimer’s Drugs Companies

この商品のレポートナンバー

0000031298

TOP